Paragon Bioservices, a US manufacturer of biopharmaceuticals and vaccines located in Baltimore, Maryland, says William Thomas has joined the company as Chief Technology Officer. In this newly-created role, he will lead the GMP Operations and Pre-Clinical Services & Process Development teams.
Thomas has more than two decades of experience in the development and manufacture of vaccines and monoclonal antibodies. He has spent the past 15 years with MassBiologics at the University of Massachusetts Medical School, where, as Deputy Director, he was responsible for product discovery, process development and manufacturing. While at MassBiologics, Thomas was responsible for the development of monoclonal antibodies against C. difficile that were shown to be effective in a Phase III trial recently completed by Merck. Additionally, under his leadership, MassBiologics modernised its manufacturing process to meet FDA standards.
Thomas began his career with OraVax (formerly Acambis, now Sanofi Pasteur) where he held a series of positions of increased responsibility and was responsible for vaccine discovery and clinical manufacturing, developing vaccines and adjuvants for use against C. difficile and H. pylori.
